Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

References

• FeifelDCommentary: why diagnose and treat ADHD in adults?Postgrad Med20081203131518824821
   PubMed Web of Science ®Google Scholar
• AshersonPClinical assessment and treatment of attention deficit hyperactivity disorder in adultsExpert Rev Neurother20055452553916026236
   PubMedGoogle Scholar
• AshersonPChenWCraddockBTaylorEAdult attention-deficit hyperactivity disorder: recognition and treatment in general adult psychiatryBr J Psychiatry20071904517197649
   PubMed Web of Science ®Google Scholar
• FaraoneSVBiedermanJMickEThe age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studiesPsychol Med20053517
   Google Scholar
• FayyadJDe GraafRKesslerRCross-national prevalence and correlates of adult attention-deficit hyperactivity disorderBr J Psychiatry200719040240917470954
   PubMed Web of Science ®Google Scholar
• KesslerRCAdlerLBarkleyRThe prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey ReplicationAm J Psychiatry2006163471672316585449
   PubMed Web of Science ®Google Scholar
• KesslerRCAdlerLABarkleyRPatterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replicationBiol Psychiatry200557111442145115950019
   PubMed Web of Science ®Google Scholar
• GreenhillLLPliszkaSDulcanMKSummary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adultsJ Am Acad Child Adolesc Psychiatry200140111352135511699811
   PubMed Web of Science ®Google Scholar
• NuttDJFoneKAshersonPEvidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol2007211104117092962
   PubMed Web of Science ®Google Scholar
• KooijJJBuitelaarJKvan den OordEJFurerJWRijndersCAHodiamontPPInternal and external validity of attention-deficit hyperactivity disorder in a population-based sample of adultsPsychol Med200535681782715997602
   PubMed Web of Science ®Google Scholar
• KooijJJBurgerHBoonstraAMVan der LindenPDKalmaLEBuitelaarJKEfficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trialPsychol Med200434697398215554568
   PubMed Web of Science ®Google Scholar
• BanaschewskiTCoghillDSantoshPLong-acting medications for the hyperkinetic disorders. A systematic review and European treatment guidelineEur Child Adolesc Psychiatry200615847649516680409
   PubMed Web of Science ®Google Scholar
• GodfreyJSafety of therapeutic methylphenidate in adults: a systematic review of the evidenceJ Psychopharmacol200923219420518515459
   PubMed Web of Science ®Google Scholar
• RostainALAttention-deficit/hyperactivity disorder in adults: evidence-based recommendations for managementPostgrad Med20081203273818824823
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse EventsRockville, MDNational Press Office2212007 Press0726
   Google Scholar
• NissenSEADHD drugs and cardiovascular riskN Engl J Med2006354141445144816549404
   PubMed Web of Science ®Google Scholar
• OkieSADHD in adultsN Engl J Med2006354252637264116790695
   PubMed Web of Science ®Google Scholar
• PelhamWEGnagyEMBurrows-MacleanLOnce-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settingsPediatrics20011076E10511389303
   PubMed Web of Science ®Google Scholar
• SwansonJGuptaSLamADevelopment of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studiesArch Gen Psychiatry200360220421112578439
   PubMed Web of Science ®Google Scholar
• WolraichMLGreenhillLLPelhamWRandomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorderPediatrics2001108488389211581440
   PubMed Web of Science ®Google Scholar
• AdlerLAZimmermanBStarrHLEfficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation studyJ Clin Psychopharmacol200929323924719440077
   PubMed Web of Science ®Google Scholar
• BiedermanJMickESurmanCA randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorderBiol Psychiatry200659982983516373066
   PubMed Web of Science ®Google Scholar
• MedoriRRamos-QuirogaJACasasMA randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorderBiol Psychiatry2008631098198918206857
   PubMed Web of Science ®Google Scholar
• ReimherrFWWilliamsEDStrongREMestasRSoniPMarchantBKA double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorderJ Clin Psychiatry20076819310117284136
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental DisordersFourth Edition, Text RevisionWashington, DCThe American Psychiatric Association2000
   Google Scholar
• ConnersCErhardtDSparrowEConners’ Adult ADHD Rating Scales (CAARS): Technical ManualNorth Tonawanda, NYMulti-Health Systems1999
   Google Scholar
• FirstMSpitzerRGibbonMWilliamsGStructured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), Version 2New York, NYNew York State Psychiatric Institute, Biometrics Research1994
   Google Scholar
• BiedermanJMickESpencerTAn open-label trial of OROS methylphenidate in adults with late-onset ADHDCNS Spectr200611539039616641844
   PubMed Web of Science ®Google Scholar
• FalluARichardCPrinzoRBinderCDoes OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorderCurr Med Res Opin200622122557256617166338
   PubMed Web of Science ®Google Scholar
• Ramos-QuirogaJABoschRCastellsXEffect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorderCNS Drugs200822760361118547128
   PubMed Web of Science ®Google Scholar
• VetterVLEliaJEricksonCCardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular NursingCirculation2008117182407242318427125
   PubMed Web of Science ®Google Scholar
• ModiNBLindemulderBGuptaSKSingle- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulationJ Clin Pharmacol200040437938810761165
   PubMed Web of Science ®Google Scholar
• BuksteinOSubstance abuse in patients with attention-deficit/hyperactivity disorderMedscape J Med20081012418324334
   PubMedGoogle Scholar